Flush, rosacea, alebo červenanie –  pochopenie rozdielov

1. Bouloux PG. Sweat­ing and flushing: evaluation and management. Presented at: ENDO 2013. June 18th, 2013. Avail­able from: http://ses­sions.endocrine.org/s/2013an/endo/M58

2. Wiel L. The time of the change: menopause’s medicalization and the gender politics of aging. International Journal of Feminist Approaches to Bioethics 2014; 7(1): 74– 98. doi: 10.2979/ intjfemappbio­.7.1.74.

3. Hyrdel P, Agouba S, Režňák I et al. Neuroendokrin­né nádory tráviaceho traktu. Gastroenterol. prax 2014; 13(4): 209– 216.

4. National Institutes of Health. National Institutes of Health State of the Science Conference statement: management of menopause-related symp­toms. Ann Intern Med 2005; 142 (12 Pt 1): 1003– 1013.

5. Ros­smanith WG, Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symp­toms in the meno­pause. Gynecological Endocrinology 2009; 25(5): 303– 314.

6. Barankin B, Guenther L. Rosacea and atopic dermatitis. Two com­mon oculocutaneous disorders. Can Fam Physician 2002; 48: 721– 724.

7. Taylor SC, David JN. Acne and Rosacea: a closer look at skin of color. [online]. Available from: http://www.medscape.org/viewarticle/770773.

8. Drake L. New studies show high incidence of rosacea and pos­sible new causes. Rosacea Review 2007. [online]. Available from: www.rosacea.org/r­r/2007/sum­mer/article_1.php.

9. Deecher DC. Physiology of thermoregulatory dysfunction and cur­rent approaches to the treatment of vasomotor symp­toms. Expert Opin Investig Drugs 2005; 14(4): 435– 448.

10. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001; 13(4): 453– 464.

11. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003; 78(5): 603– 612.

12. Kräuchi K, Wirz-Justice A. Circadian rhythm of heat production, heart rate, and skin and core temperature under unmask­ing conditions in men. Am J Physiol 1994; 267 (3 Pt 2): R819– R829.

13. Boulant JA, Dean JB. Temperature receptors in the central nervous system. An­nu Rev Physiol 1986; 48: 639– 654.

14. Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system.Am J Physiol Regul Integr Comp Physiol2007; 292(1): R37– R46.

15. Simon E. The enigma of deep-body thermosensory specificity. Int J Biometeorol 2000; 44(3): 105– 120.

16. Kyratsas C, Dal­la C, Anderzhanova E. Experimental evidence for sildenafil’s action in the central nervous system: dopamine and serotonin changes in the medial preoptic area and nucleus accumbens dur­ing sexual arousal. J Sex Med 2013; 10(3): 719– 729. doi: 10.1111/ j.1743-6109.2012.03000.x.

17. Koutcherov Y, Mai JK, Paxinos G. Hypothalamus of the human fetus. J Chem Neuroanat 2003; 26(4): 253– 270.

18. Castañeyra-Perdomo A, Pérez-Delgado MM, Montagnese C et al. Brainstem projections to the medial preoptic region contain­ing the luteiniz­ing hormone-releas­ing hormone perikarya in the rat. An im­munohistochemical and retrograde transport study. Neurosci Lett 1992; 139(1): 135– 139.

19. Dudas B, Merchenthaler I. Three-dimensional representation of the neurotransmitter systems of the human hypothalamus: inputs of the gonadotrophin hormone-releas­ing hormone neuronal system. J Neuroendocrinol 2006; 18(2): 79– 95.

20. Graham MD, Pfaus JG. Dif­ferential ef­fects of dopamine antagonists infused to the medial preoptic area on the sexual behavior of female rats primed with estrogen and progesterone. Pharmacol Biochem Behav 2012; 102(4): 532– 539. doi: 10.1016/ j.pbb.2012.06.020.

21. Orikasa C, Sakuma Y. Estrogen configures sexual dimorphism in the preoptic area of C57BL/ 6J and ddN strains of mice. J Comp Neurol 2010; 518(17): 3618– 3629.

22. Castañeyra-Ruiz L, González-Mar­rero I, Castañeyra-Ruiz A. Luteiniz­ing hormone-releas­ing hormone distribution in the anterior hypothalamus of the female rats. ISRN Anat 2013; 2013: 870721. doi: 10.5402/ 2013/ 870721.

23. Brück K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Ther 1987; 35(1– 2): 163– 215.

24. Gundlah C, Pecins-Thompson M, Schutzer WE et al. Ovarian steroid ef­fects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 1999; 63(2): 325– 339.

25. Bethea CL, Lu NZ, Gundlah C et al. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002; 23(1): 41– 100.

26. Karkanias GB, Ansonoff MA, Etgen AM. Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J Neuroendocrinol 1996; 8: 449– 455.

27. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function and clas­sification. Pharmacol Ther 1994; 62(3): 283– 324.

28. Moris­sette M, Le Saux M, D’Astous M. Contribution of estrogen receptors alpha and beta to the ef­fects of estradiol in the brain. J Steroid Biochem Mol Biol 2008; 108(3– 5): 327– 338.

29. Wool­ley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density dur­ing the estrous cycle in the rat. J Comp Neurol 1993; 336(2): 293– 306.

30. Schwarz JM, Nugent BM, McCarthy MM.Developmental and hormone-induced epigenetic changes to estrogen and progesterone receptor genes in brain are dynamic across the life span. Endocrinology 2010; 151(10): 4871– 4881. doi: 10.1210/ en.2010-0142.

31. Malik KF, Feder HH, Mor­rell JI. Estrogen receptor im­munostain­ing in the preoptic area and medial basal hypothalamus of estradiol benzoate- and prazosin-treated female guinea-pigs. J Neuroendocrinol 1993; 5(3): 297– 306.

32. Deecher DC, Dor­ries K. Understand­ing the pathophysiology of vasomotor symp­toms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007; 10(6): 247– 257.

33. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20(3): 279– 307.

34. Gould E, Wool­ley CS, Frankfurt M et al. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cel­ls in adult­hood. J Neurosci 1990; 10(4): 1286– 1291.

35. Liu X, Shi H. Regulation of estrogen receptor α expres­sion in the hypothalamus by sex steroids: implication in the regulation of energy homeostasis. Int J Endocrinol 2015; 2015: 949085. doi: 10.1155/ 2015/ 949085.

36. Lu NZ, Bethea CL. Ovarian steroid regulation of 5-HT1A receptor bind­ing and G protein activation in female monkeys. Neuropsycho-pharmacology 2002; 27(1): 12– 24.

37. Serova LI, Maharjan S, Huang A et al. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expres­sion to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res 2004; 1015(1– 2): 1– 8.

38. Karkanias GB, Etgen AM. Estradiol reduction of the agonist high affinity form of the alpha 2-adrenoceptor in the hypothalamus of female rats: identification as the alpha 2D subtype. Mol Pharmacol 1994; 45(3): 509– 516.

39. Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002; 160(3): 271– 282.

40. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteniniz­ing hormone secreation. Science 1979; 205(4408): 823– 825.

41. Family Al­lergy & Asthma Care of Montana. Do you experience flushing? Is it dry or wet flushing? [online]. Available from: www.familyal­lergyasthmacare.com/2014/01/do-you-experience-flushing-is-it-dry-or-wet-flushing.

42. Tebbi CK. Carcinoid tumor. [online]. Available from: http://emedicine.medscape.com/article/986050-overview.

43. Aldrich LB, Moattari AR, Vinik AI. Distinguish­ing features of idiopathic flush­ing and carcinoid syndrome. Arch Intern Med 1988; 148(12): 2614– 2618.

44. Geppetti P, Renzi D, Caleri C et al. In­crease of plasma substance P- and neurokinin A-like im­munoreactivity dur­ing carcinoid flushing. In: Henry JL, Couture R, Cuel­lo AC (eds). Substance P and Neurokinins. New York: Springer-Verlag 1987: 220– 222.

45. Yip J, Loris A Chahl. Localization of NK1 and NK3 receptors in guinea-pig brain. Regulatory Peptides 2001; 98(1– 2): 55– 62. doi: 10.1016/ S0167-0115(00)00228-7.

46. Gobbi G, Cas­sano T, Radja F et al. Neurokinin 1 receptor antagonism requires nor­epinephrine to increase serotonin function. Eur Neu-ropsychopharmacol 2007; 17(5): 328– 338. doi: 10.1016/ j.euroneuro. 2006.07.004.

47. Bos­sal­ler C, Reither K, Hehlert-Friedrich C et al. In vivo measurement of endothelium-dependent vasodilation with substance P in man. Herz 1992; 17(5): 284– 290.

48. Columbo M, Horowitz EM, Kagey-Sobotka A et al. Substance P activates the release of histamine from human skin mast cel­ls through a pertus­sis toxin-sensitive and protein kinase C-dependent mechanism. Clin Im­munol Im­munopathol 1996; 81(1): 68– 73.

49. Wong BJ, Tublitz NJ, Minson CT. Neurokinin-1 receptor desensitization to consecutive microdialysis infusions of substance P in human skin. J Physiol 2005; 568(3): 1047– 1056. doi: 10.1113/ jphysiol.2005.095 372.

50. Bouloux PM. What to do about flush­ing and sweat­ing disorders. [online]. Available from: http://pres­s.endocrine.org/doi/ful­l/10.1210/MTP4.9781936704941.ch32.

51. Greaves MW. Flush­ing and flush­ing syndromes, rosacea and perioral dermatitis. In: Champion RH, Burton JL, Burns T et al (eds). Rook/Wilkinson/Ebl­ing Textbook of Dermatology. 6th ed. Oxford: Blackwell Scientific 1998: 2099– 2104.

52. Izikson L, English JC 3rd, Zirwas MJ. The flush­ing patient: dif­ferential dia­gnosis, workup, and treatment. J Am Acad Dermatol 2006; 55(2): 193– 208.

53. Nasr C. Flushing. [online]. Available from: www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/flushing/.

54. Scheinfeld NS. Rosacea. Skinmed 2006; 5(4): 191– 194.

55. Al Balbeesi AO, Halawani MR. Unusual features of rosacea in saudi females with dark skin. Ochsner J 2014; 14(3): 321– 327.

56. Pray WS, Pray JJ. Dif­ferentiat­ing between rosacea and acne. US Pharmacist 2004; 29(4). [online]. Available from: www.medscape.com/viewarticle/475331.

57. Per­rot-Applanat M. Ef­fect of estrogens on vascular proliferation. Therapie 1999; 54(3): 333– 337.

58. La­ing W. Chronic venous disease of the leg. London: Of­fice of Health Economics 1992: 10– 12.

59. Özcan S, Tezcan O, Kurt T et al. Serum estradiol/ free testosterone ratio precipitate recur­rent varicose veins in men. Int Angiol 2015; 34(6): 576– 581.

60. Yamasaki K, Gal­lo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55(2): 77– 81.

61. Steinhoff M, Buddenkotte J, Aubert Jet al. Clinical, cel­lular, and molecular aspectsin the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15(1): 2– 11.doi: 10.1038/ jidsymp.2011.7.

62. Coda AB, Hata T, Mil­ler J et al. Cathelicidin, kal­likrein 5, and serine protease activity is inhibited dur­ing treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69(4): 570– 577. doi: 10.1016/ j.jaad.2013.05.019.

63. Nielsen PG. Metronidazole treatment in rosacea. Int J Dermatol 1988; 27(1): 1– 5.

64. Utaş S, Ozbakir O, Turasan A. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol 1999; 40(3): 433– 435

65. Gravina A, Federico A, Ruocco E. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J 2015; 3(1): 17– 24.

66. Bon­nar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad of Dermatol 1993; 28(3): 443– 448.

67. Gol­lnick H. Cur­rent concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003; 63(15): 1579– 1596.